Literature DB >> 30887594

Alopecia areata: a long-term follow-up study of 104 patients.

A Lyakhovitsky1, A Aronovich1, S Gilboa1, S Baum1,2, A Barzilai1,2.   

Abstract

BACKGROUND: Alopecia areata (AA) is a common autoimmune disease that considerably affects the quality of life. Although several studies have investigated the epidemiology, clinical characteristics and treatment of AA, limited recent data are available regarding its long-term course.
OBJECTIVES: To evaluate the long-term course of AA in different age groups.
METHODS: A retrospective evaluation of patients who were newly diagnosed with AA from 2008 to 2011 and had at least 7 years of follow-up. Data regarding the initial episode, treatment given, disease-free interval and relapses were analysed.
RESULTS: A total of 104 cases were analysed: 31 childhood-onset, 63 adult-onset and 10 late-onset. At first episode, 88.5% of patients had mild, 3.8% moderate and 7.7% severe AA. Full or significant re-growth was observed in 74%, 94% and 100% of childhood-onset, adult-onset and late-onset AA patients, respectively. There was no re-growth in 13%, 3% and 0% of childhood-onset, adult-onset and late-onset patients, respectively. The duration of the initial episode and the disease-free interval negatively correlated with age. Systemic steroids were the most effective treatment for the primary episode. The frequency of relapses was high overall (52%, 44% and 30% in childhood-onset, adult-onset and late-onset, respectively), but significantly declined over time with a majority (79%) occurring within the first 4 years. The disease-free interval and relapse rate were not correlated with gender, disease severity at onset or treatment given.
CONCLUSIONS: The prevalence of severe disease, duration of an initial episode and the rate of relapses decreased with an older age at onset. In addition, the outcome and the disease-free interval improved with age at onset. The frequency of relapses declined over time and most appear early on. The current treatment modalities do not seem to influence the long-term outcome.
© 2019 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2019        PMID: 30887594     DOI: 10.1111/jdv.15582

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  6 in total

1.  Prognostic Factors in Mexican Patients with Patchy and Other Types of Alopecia Areata.

Authors:  Erick Alejandro Jiménez-Herrera; Zamira Rios-Garza; María Luisa Peralta-Pedrero; Fermin Jurado-Santa Cruz; Martha Alejandra Morales-Sánchez
Journal:  Skin Appendage Disord       Date:  2020-07-20

Review 2.  Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management.

Authors:  Cheng Zhou; Xiangqian Li; Chen Wang; Jianzhong Zhang
Journal:  Clin Rev Allergy Immunol       Date:  2021-08-17       Impact factor: 8.667

3.  Genetic predisposition of alopecia areata in jordanians: A case-control study.

Authors:  Laith N Al-Eitan; Mansour A Alghamdi; Rawan O Al Momani; Hanan A Aljamal; Asim M Abdalla; Heitham M Mohammed
Journal:  Heliyon       Date:  2022-03-24

4.  Evaluation of Biopsy Results, Consultations, and Follow-Ups in Pediatric Dermatopathology.

Authors:  Vildan Manav; Yusuf Mert Döş; Duygu Erdil; Ayşe Esra Koku Aksu
Journal:  Turk Arch Pediatr       Date:  2022-09

5.  Alopecia Areata and Dexamethasone Mini-Pulse Therapy, A Prospective Cohort: Real World Evidence and Factors Related to Successful Response.

Authors:  Manuel Sánchez-Díaz; Trinidad Montero-Vilchez; Ahinoa Bueno-Rodriguez; Alejandro Molina-Leyva; Salvador Arias-Santiago
Journal:  J Clin Med       Date:  2022-03-18       Impact factor: 4.241

6.  Alopecia Areata Treatment Patterns, Healthcare Resource Utilization, and Comorbidities in the US Population Using Insurance Claims.

Authors:  Maryanne Senna; Justin Ko; Antonella Tosti; Emily Edson-Heredia; D Christian Fenske; Amy K Ellinwood; Maria Jose Rueda; Baojin Zhu; Brett King
Journal:  Adv Ther       Date:  2021-07-22       Impact factor: 3.845

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.